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the best use of expensive resources. Continued improvements to this process are 
ongoing, by incorporating off-label estimates into the original model.
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ORGANIZATION: Agency for Healthcare Research and Quality (funding organiza-
tion) Thomson Reuters. PROBLEM OR ISSUE ADDRESSED: Hospital administrative
data have been used in “cost-effectiveness”, “cost-beneﬁ t”, and “burden-of-illness” 
studies because they contain large numbers of cases for speciﬁ c conditions and proce-
dures and because charge information is available. While these data generally contain
information on how much the facility charged for the hospital stay, they lack informa-
tion on the cost to provide care and the amount reimbursed for care. In the past,
AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost of 
providing care. Currently, AHRQ is piloting a project to create price-to-charge ratios 
that will be used in conjunction with charge information collected on hospital dis-
charge records to estimate the “price” of inpatient hospital care. In developing price-
to-charge ratios, the term “price” reﬂ ects the amount that hospitals are paid by
insurers and consumers based on payer revenue information for each hospital. This 
is the amount of revenue that hospitals actually receive, net of any discounts negotiated 
with insurers. These ratios will be linked to the Healthcare Cost and Utilization Project
(HCUP) State Inpatient Databases (SID). The HCUP SID ﬁ les contain the universe of 
inpatient discharge abstracts (including information on charges) in participating
States, translated into a uniform format to facilitate multi-State comparisons and 
analyses. Currently, 40 states participate in HCUP, encompassing about 90 percent of 
all U.S. community hospital discharges. The impetus for this pilot is the President’s 
and Secretary Leavitt’s initiatives to make health care information more transparent
to consumers. While the addition of price information will help consumers make more
informed choices about hospitalizations for themselves and their families, this infor-
mation will also be valuable for researchers by providing alternatives to measuring
resource use that are better suited for their studies. GOALS: The short-term goals of 
this project include: • Explore the feasibility of creating prices for common hospital
diagnoses. • Release prices at a state-wide level for four broad payer groups (Medicare,
Medicaid, Private, and self-pay) and groupings of conditions. • Increase understanding 
of pricing differences among payers. • Release the data publicly after some internal
validation. The long term goals of this project include: • Develop price-to-charge ratios 
for all hospitals by payer states using modeling techniques. • Link price-to-charge 
ratios to the HCUP databases, which currently contain charge information and
estimate costs. • Validate estimated prices with data sources such as CMS, Market 
Scan, • Provide states with information on hospital average prices that can be used 
to populate a Website where consumers can explore pricing for common diagnoses. 
• Release prices publicly on additional AHRQ databases, including national databases
such as the Nationwide Inpatient Sample (NIS) and Kids’ Inpatient Database (KID).
OUTCOMES ITEMS USED IN THE DECISION: HCUP data have been used in 
“cost-effectiveness”, “cost-beneﬁ t”, and “burden-of-illness” studies because they 
contain large numbers of cases for speciﬁ c conditions and procedures and because
charge and estimated cost information is available. The addition of estimates prices
will provide researchers an additional tool to more effectively conduct their studies. 
IMPLEMENTATION STRATEGY: AHRQ solicited participation of HCUP Partner 
organizations that have access to hospital revenue information by payer, and are
willing to release state-level charge and price information broken out by the four broad 
payer groups and broad diagnostic categories. Initially, AHRQ is utilizing information
from 5 HCUP SID Partner States in conjunction with hospital-speciﬁ c revenue infor-
mation to develop prices for hospitalizations. RESULTS: This project is on-going and
making substantial progress. Five states with the required ﬁ nancial information have
been identiﬁ ed. The analytic methods to validate the data have been determined. The 
plan to create the price-to-charge ratios for these states is in place. An illustrative 
example of a speciﬁ c condition or procedure will be provided during the presentation
to demonstrate the differences in resource use as measured by “charges,” “costs,” and 
“prices.” An explanation of what these concepts are capturing will also be presented.
LESSONS LEARNED: To date, the project the lessons learned include: 1. The number
of States that collect ﬁ nancial information by major payers for each hospital are
limited. 5 States have been identiﬁ ed that have the detailed information required. As 
the study moves forward, our objective is to identify 8–10 states with this level of 
information. 2. While States may collect gross and net revenue information by payer,
not all separate these revenues completely for inpatient and outpatient services.
Methods will be developed to address this issue. 3. Deﬁ nitions of revenues and the
level of detailed data collection vary considerably among States. These differences will
be reconciled.
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When the measurement of a long-term outcome is necessary, selecting evidence-based 
time horizons according to pharmacoepidemiology data is crucial. OBJECTIVE: To 
illustrate the effect of assumed time horizon for the interventions in pharmacoeco-
nomic models on measured outcomes. METHODS: The beneﬁ t of reducing LDL-C 
was incorporated into a model to calculate reduction in cardiovascular events and
resulted economic outcomes. Data for LDL-C reduction from a head-to-head RCT 
[Am Heart J 2002;144:1044–51]; rosuvastatin (starting 5 mg) versus atorvastatin 
(starting 10 mg) with up-titration doses were incorporated into the model; and distri-
bution of cardiovascular risk for users [N  100,000, duration ﬁ ve years] in Canadian 
population [Clin Invest Med 2007;30:E63-E69] were assumed. To ﬁ nd out the effect
of time horizon on economic evaluation of therapeutics, the component of ﬁ ve years 
was changed to ten years time horizon. RESULTS: Using ﬁ ve years duration of therapy,
rosuvastatin and atorvastatin can prevent 9505 and 8702 cardiovascular events (non-
fatal MI and stroke), respectively. Reduction in non-fatal MI and stroke can be 
translated to $252,300,392 (CDN) and $230,980,624 direct cost savings, respectively
($288,871,921 and $158,510,416 total net-beneﬁ t). With ten years assumption 
for statin therapy, rosuvastatin and atorvastatin can prevent 25948 and 22190 car-
diovascular events, respectively. The prevention of cardiovascular events according
to the model based on ten years time horizon were calculated 2.73 and 2.55 times
higher than the ﬁ ve years based model for rosuvastatin and atorvastatin, respectively. 
CONCLUSION: This simulation study illustrates the effect of incorporated time 
horizons in pharmacoeconomic models on the resulted outcomes. Therefore, consider-
ing an evidence-based time horizon for the model is essential. For example, in this 
study Canadian community-based clinical practice data reported a median of approxi-
mately ﬁ ve years of statin therapy for the patients. Therefore, a time horizon of ﬁ ve 
years was assumed to be an evidence-based time horizon for the model.
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OBJECTIVE: To present practical methods for interpreting and displaying results from 
regression models that mitigate the risk of miscommunication and misinterpretation.
METHODS: A series of examples of correct and incorrect ways of presenting results 
from regression models will be presented from the recently published pharmacoeco-
nomics and outcomes research literature. Methods for computing expected values and
predicted probabilities from ordinary least squares (OLS) and logistic regression 
models will be presented. RESULTS: Computing and presenting expected values and 
predicted probabilities can, and have in some of the published literature, resulted in
less ambiguous and easier to interpret results. CONCLUSION: As pharmacoecono-
mists, we are called on to the present our results not only to our colleagues, but also
to policy-makers and the lay media. Therefore, it is important to make sure results 
from complicated regression analyses are properly communicated and interpreted. 
However, coefﬁ cients from all but the simplest models are often incorrectly interpreted. 
Odds ratios from logistic regression models are even more likely to be misinterpreted 
(as risk ratios). Furthermore, simply reporting odds ratios does not convey information
about the probability of outcomes occurring for reference group(s). It will be argued 
that computing and presenting the expected value, E(Y), from an OLS model and the 
predicted probability, Pr(Y), from a logistic regression can help researchers better “tell
a story” and result in less ambiguous presentations of ﬁ ndings. For example, the 
adjusted expected costs of an intervention can be computed for different doses and
for different demographic groups and the predicted probability of medication adher-
ence can also be computed as a function of different combinations of patient demo-
graphic characteristics and attitudes.
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OBJECTIVES: The cost of the drug of interest, its comparator(s) and concomitant 
drugs, are important parameters in pharmacoeconomic evaluations. Although general
methods guidelines exist, there are no speciﬁ c recommendations on drug cost estima-
tion. The aim of this study was to assess current practice in the reporting and conduct
of drug costing in Ireland and the UK, and make recommendations for improving 
future practice. METHODS: We searched the NHS Economic Evaluation Database 
for evaluations published in Ireland between 2001–2006. Due to the large number of 
UK studies, we considered only those published between 2005–2006. To assess the 
generalisability of our ﬁ ndings we included studies from Denmark, Finland and
Norway published between 2001–2006. This generated 59 studies. Data were
extracted on: name(s) of medicine(s), route of administration, source of drug cost, cost 
